BioVentix PLC Director/PDMR Shareholding
29 Enero 2024 - 9:15AM
RNS Regulatory News
RNS Number : 2629B
BioVentix PLC
29 January 2024
Bioventix
plc
("Bioventix" or "the
Company")
Director
Dealing
Bioventix plc (BVXP), a UK company
specialising in the development and commercial supply of
high-affinity monoclonal antibodies for applications in clinical
diagnostics, announces that the Company was notified today that on
29 January 2024 Peter Harrison, Chief Executive Officer of the
Company, sold 62,000 ordinary shares of 5 pence each in the Company
("Ordinary Shares"), at a price of 4,200 pence per Ordinary Share
(the "Sale").
The Sale was facilitated to enable a
new institutional investor to join the share register. Peter
Harrison has undertaken not to dispose of any further Ordinary
Shares for 12 months.
Following the Sale, Peter Harrison
has a beneficial interest in 297,088 Ordinary Shares, representing
approximately 5.7 per cent. of the issued share capital of the
Company.
The notification below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provides further details.
For
further information please contact:
|
Bioventix plc
Peter Harrison
Bruce Hiscock
|
Chief Executive Officer
Chief Financial Officer
|
Tel: 01252 728 001
|
|
|
|
|
|
Cavendish Capital Markets Limited
Geoff Nash / Simon Hicks
Nigel Birks / Harriet
Ward
|
Corporate Finance
Corporate Broking
|
Tel: 020 7220 0500
|
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Peter Harrison
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Bioventix plc
|
|
b)
|
LEI
|
213800225MHX7LZQY108
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 5 pence
each
|
|
Identification code
|
GB00B4QVDF07
|
|
b)
|
Nature of the transaction
|
Sale of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
62,000 Ordinary Shares
4,200 pence
|
|
d)
|
Aggregated information:
· Aggregated volume
· Price
|
Sale of 62,000 Ordinary Shares at 4,200 pence each
|
|
e)
|
Date of the transaction
|
29 January 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM Market
(XLON)
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHEASFNAEALEFA
Bioventix (LSE:BVXP)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Bioventix (LSE:BVXP)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
